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The NKG2D receptor is one of the most potent activating natural killer cell receptors involved in antiviral
responses. The mouse NKG2D ligands MULT-1, RAE-1, and H60 are regulated by murine cytomegalovirus
(MCMV) proteins m145, m152, and m155, respectively. In addition, the m138 protein interferes with the
expression of both MULT-1 and H60. We show here that one of five RAE-1 isoforms, RAE-1, is resistant to
downregulation by MCMV and that this escape has functional importance in vivo. Although m152 retained
newly synthesized RAE-1 and RAE-1 in the endoplasmic reticulum, no viral regulator was able to affect the
mature RAE-1 form which remains expressed on the surfaces of infected cells. This differential susceptibility
to downregulation by MCMV is not a consequence of faster maturation of RAE-1 compared to RAE-1 but
rather an intrinsic property of the mature surface-resident protein. This difference can be attributed to the
absence of a PLWY motif from RAE-1. Altogether, these findings provide evidence for a novel mechanism of
host escape from viral immunoevasion of NKG2D-dependent control.
Cytomegaloviruses (CMVs) are ubiquitous pathogens caus-
ing morbidity in immune suppressed and immunodeficient
hosts (34). Since CMVs are strictly species-specific viruses, the
infection of mice with murine CMV (MCMV) represents a
widely used model for studying CMV infection and disease
(22, 40).
Natural killer (NK) cells play a crucial role in the control of
many viruses and are among the first cells to sense proinflam-
matory cytokines, as well as the perturbations in the expression
of major histocompatibility complex (MHC) class I molecules
and other surface molecules induced by viral infection (13).
Both human CMV (HCMV) and MCMV have evolved strat-
egies to compromise innate immunity-mediated by NK cells
(20, 49).
Although proinflammatory cytokines released during the
early stage of MCMV infection induce NK cell activation, this
is usually not sufficient for virus control (11). Namely, most
mouse strains fail to mount an effector phase of NK cell re-
sponse against infected cells (42), in spite of the fact that
MCMV infection causes the downmodulation of MHC I mol-
ecules (17), which should activate NK cells via a “missing-self”
mechanism (28). The lack of NK cell activation by MCMV is
even more puzzling considering that NK cells possess activat-
ing receptors that recognize cellular ligands induced by infec-
tion. Among these is the activating receptor NKG2D, a C-type
lectinlike receptor encoded by a single gene in humans and
rodents (39). Engagement of NKG2D transduces a strong ac-
tivating signal to promote NK cell stimulation. NKG2D also
serves as a costimulatory receptor on CD8 T cells (2). Several
NKG2D ligands have been described in mice: MULT-1, H60a,
H60b, H60c, and RAE-1, -1, -1, -1, and -1ε isoforms (4–6,
10, 14, 32, 35, 44). What prevents the activation of NK cells via
the NKG2D receptor during MCMV infection? We and others
have characterized four MCMV proteins involved in the down-
modulation of NKG2D ligands (15, 23, 24, 26, 29, 30). Fur-
thermore, the deletion of any of the four MCMV inhibitors of
NKG2D ligands rendered virus mutants susceptible to NK cell
control in vivo. The MCMV immunoevasin of NKG2D de-
scribed first was the glycoprotein gp40, encoded by the gene
m152 (23). Note that m152 also compromises the CD8 T-cell
response by downregulation of MHC class I molecules (25, 54).
Later, it was noticed that m152 also affects the expression of
RAE-1 proteins (29). It is important to point out that mouse
strains express different RAE-1 isoforms. Some strains, such as
BALB/c, express RAE-1, -1, and -1, while others, such as
C57BL/6, express RAE-1 and -1ε (29). All five RAE-1 iso-
forms are glycosylphosphatidylinositol (GPI)-linked proteins
and contain MHC class I-like 1 and 2 domains (6, 10, 14, 35).
Based on our initial observation that there is NKG2D-de-
pendent control of wild type (WT) MCMV in certain mouse
strains, we postulated NKG2D ligands that resist virus medi-
ated downmodulation. We show here that the RAE-1 proteins
differ in their susceptibility to downregulation by MCMV. In
contrast to RAE-1, representing the sensitive isoform, sur-
face-resident RAE-1 remains present on MCMV-infected
cells. The differential downmodulation of RAE-1 isoforms dur-
ing MCMV infection is caused by differences in the stability of
the mature RAE-1 molecules associated with a sequence motif
absent in RAE-1.
MATERIALS AND METHODS
Mice and blockade of NKG2D. BALB/c (H-2d), C3H/J (H-2k), CBA/J (H-2k),
C57BL/6 (H-2b), and DBA/2 (H-2d) mice used in the present study were housed
under spefic-pathogen-free conditions at the Central Animal Facility, Faculty of
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Medicine, University of Rijeka. Mice were injected intravenously (i.v.) with 3 
105 PFU of tissue culture-grown WT or m157 MCMV (3). Salivary gland-
derived (SGV) MCMV was injected intraperitoneally (i.p.) at a dose of 5  104
PFU. Virus titers in tissues were analyzed at indicated days postinfection (p.i.) as
described previously (21). All of the protocols used for breeding of mice and
different kinds of treatment were approved by the Ethics Committee of the
University of Rijeka and were performed in accordance with Croatian Law for
the Protection of Laboratory Animals, which has been harmonized with the
existing EU legislation (EC Directive 86/609/EEC). Handling of animals, iden-
tification, surgical procedures, and anesthesia were performed using the recom-
mendation described in the Guide for the Care and Use of Laboratory Animals
(National Academies Press) and the Act on the Welfare of Animals (NN 19/
1999).
The blocking of NKG2D in vivo was performed by i.p. injection of anti-mouse
NKG2D monoclonal antibody (MAb; clone C7 [kindly provided by W. M.
Yokoyama]) (18) 1 day before infection. CD4 and CD8 T cells were depleted by
i.p. injection of the rat MAbs YTS191.1 and YTS169.4, respectively (8). The
statistical significance of the difference between experimental groups was deter-
mined by the Mann-Whitney exact-rank test.
Cells and transfection conditions. SVEC4-10 (ATCC CRL-2181) and NIH
3T3 (ATCC CRL-1658) cells were cultivated in Dulbecco modified Eagle me-
dium (DMEM) supplemented with 10% fetal calf serum (FCS). Mouse embry-
onic fibroblasts (MEFs) prepared from C3H/J mice were cultivated in DMEM
supplemented with 3% FCS (21). FLAG-tagged RAE-1 was cloned into the SalI
restriction site of pB45-Neo plasmid (kindly provided by E. R. Podack, Univer-
sity of Miami School of Medicine, Miami, FL) (37) to generate pB45-Neo-
RAE-1 (described in reference 1). The FLAG tag was introduced into the
RAE-1 gene (GenBank accession no. AAF97631) and the RAE-1 gene lacking
the PLWY by gene synthesis (Ezbiolab). Both synthetic open reading frames
were recloned into the SalI site of the pB45-Neo plasmid, generating pB45-Neo-
RAE-1 and pB45-Neo-RAE-1-PLWY. These plasmids carrying FLAG-tagged
RAE-1, RAE-1, and RAE-1-PLWY constructs were then transfected into
NIH 3T3 fibroblasts using SuperFect transfection reagent (Qiagen) according to
the manufacturer’s instructions, and the cell lines NIH-RAE-1, NIH-RAE-1,
and NIH-RAE-1-PLWY expressing the respective constructs were selected in
DMEM supplemented with 10% FCS and 750 g of G418 (Sigma)/ml.
Viruses. A bacterial artificial chromosome (BAC)-derived MCMV, MW97.01,
has previously been shown to be biologically equivalent to the MCMV Smith
strain (ATCC VR-1399) and is referred to here as WT MCMV (47). MCMV-gfp
recombinant virus, a derivative of the MCMV strain MW97.01 is here referred
to as WT-gfp MCMV (33). The recombinant strains lacking the m152 or m157
gene (MCMV-m152 and MCMV-m157, respectively) were propagated as
described previously (3, 46). Tissue culture-grown virus preparations were used
for in vivo and in vitro experiments (21). SGV-MCMV was used as a third
passage and prepared as described elsewhere (21).
Flow cytometry. SVEC4-10, NIH 3T3, or RAE-1-transfected cells or C3H/J
MEFs were infected with WT MCMV or mutant viruses. Cells were harvested
after 2 to 12 h, washed in fluorescence-activated cell sorting medium, and then
stained with phycoerythrin (PE)-labeled NKG2D-tetramer (23), biotinylated-
mouse anti-FLAG M2 (Sigma) MAb, rat anti-MULT-1 MAb (24), rat anti-RAE-
1 (R&D Systems), rat anti-RAE-1ε (R&D Systems), rat anti-RAE-1ε
MAb (R&D Systems), or mouse anti-RAE-1 MAb (immunoglobulin G1
[IgG1], clone RD33). The latter was generated by immunizing mice with bacu-
lovirus-expressed RAE-1 (4), followed by standard hybridoma generation using
the Ag8x63 fusion partner. The binding of primary MAbs was visualized by
streptavidin-PE, PE-labeled goat anti-rat IgG (Caltag), fluorescein isothiocya-
nate-labeled goat anti-rat IgG F(ab)2 (Santa Cruz Biotechnology), or biotinyl-
ated goat anti-mouse IgG following fluorescein isothiocyanate- or PE-labeled
streptavidin (BD Pharmingen).
Confocal microscopic analysis. RAE-1-transfected NIH 3T3 cells were in-
fected for 12 h with 4 PFU per cell of WT MCMV or m152 MCMV or left
uninfected. The cells were washed in phosphate-buffered saline (PBS) and fixed
and permeabilized using ice-cold methanol or fixed in 2.5% paraformaldehyde
and permeabilized using 0.1% Triton X-100. Unspecific binding was blocked in
0.2% fish skin gelatin. The MAbs used are described above in the flow cytometry
section. Samples were analyzed with Olympus FV300 confocal laser scanning
microscope.
Immunoprecipitation and Western blotting. The cells were mock treated or
infected, as indicated in the specific experiments. The proteins were extracted by
using NP-40 lysis buffer (150 mM NaCl, 10 mM Na3PO4 [pH 7.2], 1 mM
phenylmethylsulfonyl fluoride, 2 mM EDTA [pH 8], 1% NP-40) for 20 min on
ice. To analyze the RAE-1 maturation by Western blotting the cell lysates (100
to 150 g of proteins) were incubated with 5 mU of EndoH (Roche) at 37°C
overnight. If it was required to inhibit glycosylation, the cells were treated before
the lysis with tunicamycin (2 g/ml) for the indicated period of time. For immu-
noprecipitation, the lysates were precleared with protein G-Sepharose (Amer-
sham), followed by the incubation with anti-FLAG M2 Sepharose (Sigma) for 60
min. The Sepharose beads were then washed and eluted (5 min, 95°C) with
nonreducing loading buffer (200 mM Tris [pH 8.8], 1 M sucrose, 1% sodium
dodecyl sulfate [SDS], 5 mM EDTA [pH 8.0], 0.02% bromophenol blue) and
separated by SDS-polyacrylamide gel electrophoresis (PAGE) using an 11.5%
gel. The separated proteins were transferred to Hybond-C membrane (Amer-
sham), and the specific signals were obtained by using rat anti-RAE-1ε MAbs
(R&D Systems) and polyclonal goat anti-RAE-1 (R&D Systems), followed by
peroxidase-labeled goat anti-rat F(ab)2 antibodies (Amersham) and rabbit anti-
goat IgG (Wako), respectively. Detection was performed with BM chemilumi-
nescence Western blot kit (Roche).
For cell surface biotinylation, RAE-1 transfectants were grown in 12-well
plates, washed twice with PBS before biotinylation buffer (10 mM
Na2B4O7  10H2O, 5 mM NaCl, 2 mM CaCl2, 1 mM MgCl2 [pH 8.8]) containing
0.05 mg of Sulfo-NHS-SS-Biotin (Pierce)/ml was added. The biotinylation reac-
tion was performed on ice and stopped after 20 min with the cold stop solution
(10 mM glycine in PBS) for 10 min on ice. After three washes with PBS, medium
supplemented with 10% fetal bovine serum was added, and the cells were
incubated for different periods of time. Cells were lysed by using NP-40 lysis
buffer for 20 min on ice. The immunoprecipitation was performed with anti-
FLAG M2 Sepharose (Sigma), followed by immunoblotting by SA-POD
(Roche). Detection was performed with a BM chemiluminescence Western blot
kit (Roche).
For metabolic labeling, cells were labeled either with 300 Ci of [35S]methi-
onine (Amersham)/ml for 2 h or with 500 Ci of [35S]methionine/ml for 1 h at
37°C, washed, and chased at 37°C for the indicated periods of time in DMEM
supplemented with 10% FCS. The cells were then washed in PBS and lysed in
NP-40 lysis buffer. The cell lysates were precleared with protein G-Sepharose
(Amersham), incubated for 1.5 h at 4°C either with 3 g of anti-RAE-1ε
MAbs (R&D Systems), goat anti-RAE-1 antibodies (R&D Systems), or anti-
RAE-1 MAbs (eBioscience), followed by 1.5 h of incubation with 60 l of
protein G-Sepharose (Amersham). Samples were eluted (5 min, 95°C) with the
reducing loading buffer (200 mM Tris [pH 8.8], 1 M sucrose, 1% SDS, 5 mM
EDTA [pH 8.0], 0.02% bromophenol blue, 0.05 M dithiothreitol). If EndoH
treatment was performed, the beads were eluted in 100 mM citrate buffer (pH
5.6) containing 10 mM -mercaptoethanol (Sigma) and 2 mM phenylmethylsul-
fonyl fluoride (5 min, 95°C) and then treated with 10 mU of EndoH for 12 h or
left untreated. Samples were boiled on 95°C and separated by SDS–11.5%
PAGE. Dried gels were analyzed by autoradiography by exposition of Bio-
MaxMR films (Kodak) at 	80°C for 2 to 3 days.
RESULTS
NKG2D-dependent control of MCMV in vivo. We and oth-
ers reported that downmodulation of NKG2D ligands prevents
the NK cell response in BALB/c mice to WT MCMV infection
(23, 29). This is in accordance with in vitro studies showing the
complete absence of NKG2D ligands on BALB/c-derived
fibroblasts infected with WT MCMV using NKG2D tetramers.
In an attempt to explain the resistance of different mouse
strains to early MCMV infection, we noticed that in some
mouse strains the blocking of NKG2D activity by in vivo ad-
ministration of anti-NKG2D MAbs resulted in a modest but
consistent increase of virus titers in spleen compared to
BALB/c mice, where no effect could be detected (Fig. 1A).
This effect of NKG2D blocking was less pronounced in lungs,
as well as in liver (data not shown). Note that CBA/J, C3H/J,
and C57BL/6 mice express RAE-1 and -1ε in contrast to
BALB/c mice, which express RAE-1, -1, and -1 (see sup-
plemental Fig. S1 [http://www.medri.hr/
jstipan/jonjic/]). To
test the putative role of NKG2D at later stages of infection,
C57BL/6 mice were treated with blocking anti-NKG2D MAbs
either alone or in combination with anti-CD4 and anti-CD8
MAbs to deplete T cells. As shown in Fig. 1B, even at 7 days
p.i. anti-NKG2D treatment had only modest effects on virus
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titers in lungs. However, when anti-NKG2D was combined
with T-cell depletion, an increase of virus titer was observed
exceeding the titers observed by depletion of T cells alone.
Thus, the results indicated that the role of NKG2D in NK
cell-dependent virus control is detectable in the absence of T
cells. The effect of NKG2D blocking was not restricted to
control of low-virulent tissue culture-grown MCMV since sim-
ilar results were obtained in DBA/2 mice 11 days p.i. with the
more virulent SGV MCMV (Fig. 1C). These findings prompted
us to investigate whether the NKG2D-dependent antiviral activity
in WT MCMV-infected mice is a consequence of differential
susceptibility of NKG2D ligands to viral regulation.
RAE-1 is exempt from the downregulation by MCMV. We
analyzed the expression of NKG2D ligands on the cell lines
derived from individual mouse strains. In contrast to WT
MCMV-infected NIH 3T3 cells, in which infection abolishes
the expression of NKG2D ligands, SVEC4-10 cells (C3H/J
derived) showed only partial reduction of NKG2D binding
(Fig. 2A). Specific MAbs demonstrated MULT-1, RAE-1,
and RAE-1ε on the plasma membrane of SVEC4-10 cells,
whereas H60 and RAE-1, -1, and -1 were absent (Fig. 2B).
In addition, WT MCMV infection resulted in complete down-
modulation of surface MULT-1 and RAE-1ε, whereas the ex-
pression of RAE-1 was preserved (Fig. 2C). Similar results
were obtained with primary MEFs derived from C3H/J (Fig.
2D), CBA/J, and C57BL/6 mice, as well as with C57BL/6-
derived cell lines TpnT and IC-21 (data not shown). Alto-
gether, the results showed that RAE-1 escapes MCMV-me-
diated downregulation.
m152 abolishes the surface expression of RAE-1 but does
not prevent the expression of RAE-1. Downmodulation of
RAE-1 molecules is mediated by MCMV m152 (23, 29). Con-
ventional mouse strains express either RAE-1, -1, and -1 or
RAE-1 and -1ε (29). To avoid the possible impact of MHC
class I haplotypes on the susceptibility of RAE-1 isoforms to
regulation by MCMV, we generated NIH 3T3 cells stably
transfected with RAE-1 and RAE-1. The cell lines were
infected with either WT MCMV, the mutant lacking the m152
gene (m152), or left uninfected, and the surface expression of
RAE-1 was analyzed at different time points p.i. In accordance
with published data (29), MCMV infection led to downmodu-
lation of RAE-1, which was visible already 4 h p.i. (Fig. 3A,
left). The effect was m152 dependent, since the level of
RAE-1 expression in m152 mutant-infected cells was com-
parable to that of not infected cells. In contrast, the expression
of RAE-1 on infected cells was only marginally affected (Fig.
3A, right). Similar to WT MCMV, the m152 revertant virus
strain (19) showed differential effect on RAE-1 and RAE-1
(see supplemental Fig. S2A [http://www.medri.hr/
jstipan
/jonjic/]).
FIG. 1. NKG2D-dependent virus control in vivo. (A) CBA/J, C3H/J, and BALB/c mice were injected i.v. with 3  105 PFU of WT MCMV
(MW97.01). C57BL/6 mice received the same dose of m157 MCMV. Mice were injected i.p. with PBS or with blocking anti-NKG2D MAbs. Virus
titers were determined 3 days p.i. There were significant differences in virus titers in spleen between the groups of untreated mice and groups
treated with anti-NKG2D MAbs: for CBA/J mice (P  0.008) and for C57BL/6 mice (P  0.038). Because of small number of animals per group
(n  3) for C3H/J mice, although the virus titer differences are indicative, there were no statistically significant differences. (B) C57BL/6 mice,
injected i.p. with either PBS or blocking NKG2D MAbs either alone or in combination with cytolytic anti-CD4 and anti-CD8 MAbs, were injected
i.v. with 2  105 PFU of m157 virus. Virus titers were determined 7 days p.i. There were significant differences between the untreated group and
the T-cell-depleted group (P  0.029), as well as between the untreated group and the group treated with anti-NKG2D, anti-CD4, and anti-CD8
MAbs (P  0.049). (C) DBA/2 mice were injected i.p. with PBS or blocking NKG2D MAbs or, in addition, with cytolytic anti-CD4 and anti-CD8
MAbs. The mice were also injected i.p. with 5  104 PFU of SGV-WT MCMV. Virus titers were determined 11 days p.i. There were significant
differences between the untreated group and the T-cell-depleted group (P  0.049), as well as the untreated group and the group treated with
anti-NKG2D, anti-CD4, and anti-CD8 MAbs (P  0.029). Titers for individual mice (circles) and median values (horizontal bars) are shown.
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m152 differentially affects the maturation pattern of
RAE-1 and RAE-1. To gain insight into the mechanism of
RAE-1 isoform control by MCMV, we performed immunopre-
cipitation and confocal analysis on the RAE-1 and RAE-1
transfectants. Uninfected, WT MCMV-infected, or m152
mutant-infected cells were analyzed 12 h p.i. In contrast to
RAE-1 precipitated from control cells or cells infected with
m152 mutant, additional RAE-1 forms of lower molecular
FIG. 2. Different susceptibilities of NKG2D ligands to MCMV. (A) NIH 3T3 and SVEC4-10 cells were infected for 12 h with one PFU of
WT-gfp MCMV/cell or left uninfected. Cells were stained with PE-labeled NKG2D tetramer (filled histograms). AV-PE was used as a control
(open histograms). (B) Expression of NKG2D ligands on SVEC4-10 cells was tested by specific MAbs: rat anti-MULT-1, mouse anti-RAE-1, rat
anti-RAE-1ε, rat anti-RAE-1, and rat anti-H60, followed by biotinylated-goat anti-rat IgG or biotinylated-goat anti-mouse IgG and PE-labeled
streptavidin (filled histograms). Isotype-matched rat IgG2a and mouse IgG1 MAbs were used as a negative control (open histograms).
(C) SVEC4-10 and (D) C3H/J derived MEFs were infected for 12 h with one PFU of WT-gfp MCMV/cell or left uninfected. Cells were stained
with PE-labeled NKG2D tetramer or with MAbs to RAE-1, RAE-1ε, and MULT-1 (filled histograms). Isotype-matched irrelevant MAbs and
AV-PE were used as controls for staining with specific antibodies and tetramer, respectively (open histograms).
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size were immunoprecipitated from the lysate of WT MCMV-
infected cells (Fig. 3B). The same results were obtained on
transfectans expressing RAE-1 and RAE-1 after infection
with BAC-derived m152 revertant virus (see supplemental Fig.
S2B posted at http://www.medri.hr/
jstipan/jonjic/). The effect
of m152 on RAE-1 was also revealed by accumulation of
bands of lower molecular weight representing the immature
protein. However, in contrast to RAE-1, the loss of mature
RAE-1 protein was almost complete in lysates of WT
MCMV-infected cells and RAE-1 was also not detectable on
the surface of WT MCMV-infected cells by confocal micros-
copy (Fig. 3C). The infection with m152 MCMV resulted in
the preservation of RAE-1 display.
This accumulation of lower-molecular-weight forms of
RAE-1 and RAE-1 resembles the m152 effect on MHC class
I molecules, which are retained in the endoplasmic reticulum
(ER)-Golgi intermediate compartment (ERGIC) (54). How-
ever, the RAE-1 expression on the surface of infected cells is
in clear contrast to RAE-1 and MHC class I downregulation.
One explanation for this could be that newly synthesized
RAE-1 can bypass the m152 block; alternatively, the mature
cell membrane form of RAE-1 might be more stable than
RAE-1, or RAE-1 might mature and transverse to the cell
surface at a faster rate, thus being less sensitive to control by an
MCMV early gene such as m152.
The PLWY motif determines resistance of RAE-1 to
MCMV. In an attempt to explain the differential susceptibility
of RAE-1 to MCMV, we aligned the sequence of RAE-1
isoforms (Vector NTI AlignX; NCBI Pub-Med database
search) (Fig. 4A). As described previously (6), the sequences
are highly conserved. However, among other differences, the
amino acid sequence PLWY (amino acids 49 to 52) present in
RAE-1, -1, and -1 was absent in RAE-1, whereas a LPWC
sequence in RAE-1ε was found at the same position. There-
FIG. 3. m152 affects the maturation of RAE-1 proteins. RAE-1- and RAE-1-transfected NIH 3T3 cells were infected with four PFU of WT
MCMV or m152 MCMV/cell or left uninfected. Cells were analyzed with specific anti-RAE-1 MAbs by flow cytometry (A), by immunoblotting
(IB) after immunoprecipitation (IP) with anti-FLAG M2 Sepharose (B), and by confocal microscopy (C).
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fore, transfectants of RAE-1 with an insertion of the PLWY
were generated (RAE-1-PLWY) and tested for the effect of
WT MCMV and m152 MCMV (Fig. 4B). The insertion of
the PLWY motif into the RAE-1 sequence indicated RAE-1
susceptibility to MCMV regulation. These findings were cor-
roborated by IP (Fig. 4C) and confocal studies (Fig. 4D).
Clearly, and in contrast to WT RAE-1 showing both imma-
ture and mature forms in lysates of cells infected with WT
MCMV, only the immature form of the RAE-1-PLWY could
be precipitated from WT MCMV-infected cells. Two models
of PLWY regulation of RAE-1 isoforms are possible. First,
PLWY itself could serve as a site for the interaction of RAE-1
with m152 and, second, the PLWY sequence might affects the
maturation of the RAE-1 molecules. The lower molecular
weight of the mature RAE-1-PLWY suggests an effect of the
motif on RAE-1 glycosylation (Fig. 4C).
m152 does not affect the mature form of RAE-1. Due to the
presence of m152 in MCMV-infected cells, the MHC class I
proteins mature only to the stage of EndoH-sensitive glyco-
sylation, indicating that the protein does not exit the ER (54).
We tested whether the RAE-1 forms of lower molecular
weight represent proteins retained by the m152 in a compart-
ment with ERGIC/cis-Golgi properties (Fig. 5A). The EndoH
treatment of lysates from WT MCMV-infected cells showed
that the lower molecular band of RAE-1 is EndoH sensitive.
However, we noticed a shift in mobility after EndoH treatment
even in case of mature forms of RAE-1 and RAE-1, sug-
gesting that some of the N-linked carbohydrate chains are still
EndoH sensitive. Similar findings were observed for some
other cellular (38, 52) and viral (31) glycoproteins.
The results presented above demonstrated that m152 can
retain immature RAE-1 in the ER despite simultaneous sur-
face expression of this ligand observed on the WT MCMV-
infected cells. We therefore tested whether this discrepancy
could be explained by the incomplete block of newly synthe-
sized RAE-1. o that aim, the cells were labeled with
[35S]methionine between 6 to 8 h p.i. and chased for different
periods of time (Fig. 5B). From uninfected cells at zero time of
chase both RAE-1 forms, the lower- and higher-molecular-
weight bands, corresponding to immature and mature forms,
were immunoprecipitated. As early as after 2 h of chase, a
complete maturation of RAE-1 was observed. However, in
WT MCMV-infected cells the protein remained immature
throughout the chase period (Fig. 5B), similar to the effect of
m152 on MHC class I molecules (54).
Next, we tested RAE-1 maturation in comparison to
RAE-1 maturation. To that aim, RAE-1 and RAE-1 trans-
fectants were pulsed with [35S]methionine for 1 h and chased.
FIG. 4. The PLWY motif of RAE-1 protein modulates sensitivity to MCMV. (A) Comparison of the amino acid sequences of RAE-1 isoforms
using the Vector NT AlignX program (NCBI Pub-Med database search). The PLWY motif (amino acids 49 to 52) is marked. (B) RAE-1-,
RAE-1-, and RAE-1-PLWY-transfected NIH 3T3 cells were infected for 12 h with the indicated viruses and analyzed for the expression of
RAE-1 isoforms using the anti-FLAG M2 MAb. (C and D) RAE-1- and RAE-1-PLWY-transfected NIH 3T3 cells were infected for 12 h with
four PFU of indicated viruses/cell and analyzed either by immunoblotting (IB) using the anti-RAE-1 MAbs after the immunoprecipitation (IP)
with anti-FLAG-M2 Sepharose (C) or by confocal microscopy (D).
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As shown in the Fig. 5C, the rate of maturation of RAE-1 was
comparable to that of RAE-1. As early as after 1 h of chase,
RAE-1 reached the fully mature form, whereas a small pro-
portion of RAE-1 remained EndoH sensitive. These results
strongly argue against different maturation rates as a reason
for resistance to MCMV infection.
We then tested whether surface expression of RAE-1 in
WT MCMV-infected cells is a consequence of the inability of
the virus to affect the RAE-1 that had matured already prior
to infection and m152 expression. To that aim, RAE-1 or
RAE-1 transfectants were pulsed with [35S]methionine for 2 h
prior to infection and chased for up to 12 h. As shown in Fig.
5E, RAE-1 reached the mature form and remained in this
form stably expressed also in WT MCMV-infected cells. The
results document a differential susceptibility of immature and
mature forms of RAE-1 to MCMV. In addition, there were
differences between the half-lives of mature RAE-1 and
RAE-1 proteins (Fig. 5E). Prior to chase, both immature and
FIG. 5. Differential stability of RAE-1 and RAE-1mature forms. (A) RAE-1-transfected NIH 3T3 cells were infected with four PFU of WT
MCMV or m152 MCMV/cell or left uninfected. RAE-1 was immunoblotted from EndoH-treated or untreated lysates with anti-RAE-1 MAbs.
(B) RAE-1- or empty vector-transfected NIH 3T3 cells were infected with four PFU of WT MCMV or left uninfected. Cells were metabolically
labeled with 300 Ci of [35S]methionine/ml 6 h to 8 h after infection and chased for the indicated periods of time, and immunoprecipitation was
performed using anti-RAE-1 MAbs, followed by protein G-Sepharose. (C) RAE-1- or RAE-1-transfected NIH 3T3 cells were labeled with 500
Ci of [35S]methionine/ml for 1 h and chased for the indicated periods of time. After immunoprecipitation with either anti-RAE-1 or
anti-RAE-1 MAbs followed by protein G-Sepharose, eluted proteins were treated with EndoH or left untreated. (D) RAE-1-, RAE-1-, and
RAE-1-PLWY-transfected NIH 3T3 cells were untreated or treated for 12 h with tunicamycin (2 g/ml). Cell lysates were immunoblotted using
specific anti-RAE-1 antibodies. (E) RAE-1-, RAE-1-, or empty vector-transfected NIH 3T3 cells were metabolically labeled with 300 Ci of
[35S]methionine/ml for 2 h before infection with four PFU of WT MCMV. Cells were chased for indicated periods of time and immunoprecipi-
tation was performed with either anti-RAE-1 MAbs or anti-RAE-1 antibodies followed by protein G-Sepharose. (F) RAE-1-, RAE-1-, and
RAE-1-PLWY-transfected NIH 3T3 cells were surface biotinylated. After the indicated periods of time, RAE-1 molecules were immunopre-
cipitated using anti-FLAG M2-Sepharose, followed by immunoblotting with SA-POD. Arrows indicate different maturation forms of RAE-1
proteins: R, resistant to EndoH; S, sensitive to EndoH; D, digested with EndoH. RAE-1 Tun.R indicates the matured form of RAE-1 which is
resistant to tunicamycin, whereas RAE-1 Tun.S indicates the deglycosylated form of RAE-1 proteins by tunicamycin.
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mature RAE-1 forms were present, similar to RAE-1,
whereas during chase mature RAE-1 protein were also lost
from the lysates of uninfected and MCMV-infected cells. How-
ever, the disappearance of the mature RAE-1 protein was
faster during infection conditions.
The PLWY motif determines the stability of RAE-1 proteins.
The lack of a PLWY motif determined the resistance of sur-
face RAE-1 to MCMV (Fig. 4), and its role in the RAE-1
glycosylation pattern has been indicated. Since RAE-1 sur-
face expression in WT MCMV-infected cells cannot be ex-
plained by escape of newly synthesized RAE-1 from the
m152-mediated export block (Fig. 5B), we tested whether the
PLWY motif defines the stability of RAE-1 isoforms. There-
fore, RAE-1, RAE-1, and RAE-1-PLWY transfectants
were treated with the glycosylation inhibitor, tunicamycin, and
surface biotinylation was carried out. RAE-1 proteins were
immunoblotted from the lysates of the untreated cells or cells
incubated with tunicamycin (Fig. 5D). The mature form of
RAE-1 was visualized in untreated cells, whereas, after 12 h
of tunicamycin treatment, mainly the immature, unglyco-
sylated form of protein was detected. A similar effect on
RAE-1 was observed upon the cycloheximide treatment (data
not shown). In contrast, a significant fraction of mature
RAE-1 was still present after 12 h of tunicamycin treatment.
The differential stability of the mature RAE-1 and RAE-1
forms was affected by the presence of PLWY, since the mature
form of RAE-1-PLWY showed the pattern of RAE-1. The
same differences between RAE-1, RAE-1, and RAE-1-
PLWY were seen when the analysis addressed mainly the sta-
bility of surface resident molecules by biotinylation (Fig. 5F).
The reduction of the RAE-1 signal during a 12 h period after
surface labeling is small compared to the short half-life of
RAE-1 and RAE-1-PLWY. Altogether, the differential sus-
ceptibility of surface RAE-1 and RAE-1 to downregulation
during MCMV infection is determined by the PLWY motif
which affects the intrinsic stability of the mature protein forms.
DISCUSSION
NKG2D is a dominant NK cell activating receptor present
on almost all human and mouse NK cells. HCMV and MCMV
encode a set of immunevasins which avoid activation of this
receptor through downmodulation of NKG2D ligands (20).
We report here the inability of MCMV to downmodulate
RAE-1 from the surfaces of infected cells. Our results also
showed the functional significance of RAE-1 escape from
MCMV regulation. Although m152 is able to affect all RAE-1
isoforms, it affects only their immature forms. We show that
RAE-1 and RAE-1 isoforms possess intrinsic differences
with respect to the stability of their mature forms. The differ-
ential stability of RAE-1 proteins and their susceptibility to
MCMV is associated with a PLWY motif which affects RAE-1
glycosylation and leads to the shorter half-life of the mature
RAE-1 that possesses this motif.
After cotransfection of 293T cells with m152 and RAE-1
cDNAs (, , , , or ε), all RAE-1 proteins were found to be
susceptible to the impact of m152 (29). We have shown that
the molecular mechanism of the m152-mediated effect is the
retention of RAE-1 molecules in the ER/cis-Golgi compart-
ment. However, in contrast to the model used by Lodoen et al.
in which the m152 effect was tested in isolation, we used here
cell lines that constitutively or stably express RAE-1. In the
present study, we found that MCMV is unable to downregulate
surface-resident RAE-1. It is of note that RAE-1 proteins are
rapidly induced (6, 16) also upon MCMV infection (29, 44).
We demonstrate that newly synthesized RAE-1 molecules ma-
ture in less than 2 h. It is to be expected that after MCMV
infection significant amounts of RAE-1 proteins are displayed
on the plasma membrane well before the function of m152 can
take place.
The m152 was first described by its ability to cause the
retention of MHC class I in the ER/cis-Golgi compartment
(54). The cytoplasmic tail and the transmembrane region of
m152 are not relevant for the MHC class I retention by m152
(53). Since RAE-1 proteins are GPI anchored (6, 10), the
logical presumption was that the luminal domain of m152 is
also involved in its effect on RAE-1. The m152 and MHC class
I molecules do not coprecipitate (53), and we were also unable
to find complexes of the m152 with RAE-1. Although m152 is
able to affect all mouse MHC class I haplotypes (54), there are
allele-specific differences in MHC class I downregulation (46).
Although all RAE-1 proteins are targets for m152, the
RAE-1 isoform shows the highest degree of susceptibility
(29). When we first noticed RAE-1 resistance to MCMV, we
predicted that m152 might have lower affinity for this isoform
and, in that way, a substantial portion of RAE-1 could escape
m152-mediated blocking. However, immunoprecipitation–
Western blot analysis showed nascent RAE-1 susceptibility.
The m152-retained RAE-1 molecules were not degraded,
which resembles the m152 effect on MHC class I molecules (53).
The differential stability of the mature RAE-1 and -1 was
lost after the insertion of PLWY motif in the RAE-1 se-
quence. The PLWY motif did not affect RAE-1 susceptibility
to m152 but affected the stability of the ligand. Insertion of
PLWY in RAE-1 resulted not only in the altered sensitivity to
MCMV but also in a significantly lower molecular weight of
precipitated proteins resembling the pattern of RAE-1. One
could speculate that RAE-1 is differently glycosylated due to
the structural effect of the missing PLWY. The crystal struc-
ture of murine RAE-1 (27) can serve as a template to deter-
mine the PLWY-containing loop and its relationship to the
N-linked carbohydrate addition sites. As shown elsewhere (see
supplemental Fig. S3 [http://www.medri.hr/
jstipan/jonjic/]),
the PLWY loop lies close to the N70 glycosylation site, while
the surface representation shows that both are in a prominent
solvent-exposed region. The lack of PLWY, as observed in
RAE-1, would eliminate the bulky PLWY exposed loop and
possibly make N70 more accessible as well. In other words,
PLWY might limit the accessibility of N70 to the glycosylation
machinery needed for the full maturation of RAE-1 molecules.
Certain human ligands of NKG2D receptor also show dif-
ferential resistance to viral inhibitors. HCMV UL16 arrests
ULBP-1, ULBP-2, and MICB proteins in the ER, but not the
ULBP-3, ULBP-4, and MICA family members (9, 12, 41, 48,
51). Sequence differences in the MICA and MICB 2 domains
precluded UL16 from binding to MICA and, in addition, the
replacement of the MICA 2 domain with the MICB 2 do-
main resulted in the UL16-sensitive recombinant protein (43).
However, another HCMV-encoded viral inhibitor, UL142, was
later characterized as a specific downregulator of MICA (7,
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50). Interestingly, UL142 is not able to affect surface expres-
sion of all MICA alleles; the truncated form of MICA, which
is the most common, is completely resistant to the HCMV
regulation (55). The K5 protein of the Kaposi sarcoma-asso-
ciated herpesvirus downregulates the NKG2D ligands MICA
and MICB, as well as the AICL ligand for the NKp80 receptor
(45). As in the case of UL142, the truncated MICA form
lacking the cytoplasmic tail is resistant to K5.
Variations in RAE-1 isoforms are probably consequences of
selective pressure of the virus during the evolution. The unique
absence of PLWY motif in RAE-1 may represent a host
escape from MCMV. Another counterpart of RAE-1, RAE-1ε,
possesses a LPWC motif instead of PLWY. Recently, we could
show that deletion of m152 only is not sufficient to prevent
downmodulation of RAE-1ε. MCMV has other means to com-
plete RAE-1ε downmodulation, namely, the viral protein
m138/fcr1 (1). RAE-1ε possesses the highest affinity for the
NKG2D receptor of all RAE-1 isoforms. Notably, RAE-1 has
the lowest affinity (5, 36). This might explain a more intensive
viral effort to regulate RAE-1ε than RAE-1 surface expres-
sion. Still, the phenomenon of RAE-1 resistance in vivo
points to a threat to the virus since the increased resistance of
some mouse strains to acute MCMV infection can be attrib-
uted to NK/NKG2D-mediated control. Thus, the results pre-
sented here emphasize a continuous evolutional struggle be-
tween viruses and their hosts. NKG2D, as a dominant
activation receptor important not only for the innate but also
for the adaptive immune response, is an obvious target.
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